Questions Linger Over Coverage-With-Evidence-Development Guidance
This article was originally published in The Gray Sheet
Executive Summary
CMS' latest direction on coverage with evidence development has small manufacturers still guessing how far the agency intends to extend its oversight and how much of the burden of fulfilling CMS' goals will fall to firms
You may also be interested in...
Bioethicists Advocate Cost Criterion For Coverage With Evidence Development
Pricier medical technologies might be better candidates for Medicare coverage conditioned on collection of evidence than less costly products, National Institutes of Health bioethicists suggest
Bioethicists Advocate Cost Criterion For Coverage With Evidence Development
Pricier medical technologies might be better candidates for Medicare coverage conditioned on collection of evidence than less costly products, National Institutes of Health bioethicists suggest
CMS Should Clarify Coverage For Device Trials, Manufacturers Say
Device manufacturers are asking for a clearer path to Medicare coverage of their clinical studies